Loading...
•
Mar 31, 2023
PTC Therapeutics Q1 2023 Earnings Report
PTC Therapeutics reported strong revenue growth driven by double-digit year-over-year revenue increases across its marketed and partnered products and is on track to share readouts from four clinical studies.
Key Takeaways
PTC Therapeutics reported a total revenue of $220.4 million for Q1 2023, a 48% increase compared to Q1 2022. The company is progressing with clinical studies and anticipates readouts from four clinical studies in the second quarter of 2023.
Total revenue for Q1 2023 was $220.4 million, representing a 48% year-over-year growth.
DMD franchise revenue reached $170 million in Q1 2023, a 33% increase year-over-year.
Translarna quarterly net product revenue was $115 million, driven by new patients and geographic expansion.
Emflaza quarterly net product revenue was $55 million, driven by new patients and broader access.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Revenue by Segment
Translarna Revenue
CapyFin.comEmflaza Revenue
CapyFin.comDMD Franchise Revenue
CapyFin.com Forward Guidance
PTC reaffirms its full year 2023 revenue guidance.
Positive Outlook
- Total revenues for the full year 2023 are anticipated to be between $940 million and $1.0 billion.
- Net product revenues for the DMD franchise for the full year 2023 are anticipated to be between $545 and $565 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income